Skip to content
Homepage
Author:
SOLIGENIX, INC.
Posted Date:
June 8, 2026
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
SOLIGENIX, INC.
June 8, 2026
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
SOLIGENIX, INC.
May 26, 2026
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
SOLIGENIX, INC.
May 8, 2026
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
SOLIGENIX, INC.
May 7, 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
SOLIGENIX, INC.
May 4, 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
SOLIGENIX, INC.
May 4, 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet’s Disease
SOLIGENIX, INC.
May 3, 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
SOLIGENIX, INC.
May 3, 2026
Soligenix Announces HyBryte™ Clinical Summary Published in “Expert Opinion on Investigational Drugs”
SOLIGENIX, INC.
May 3, 2026
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
SOLIGENIX, INC.
May 1, 2026
1
2
Next
